Cassava Sciences, Inc. ( SAVA ) shares are trading higher Monday. Here’s what you need to know.

What To Know: Cassava Sciences ( SAVA ) is scheduled to hold a conference call on Thursday, August 8 2024, to discuss recent developments and provide a company update. Analysts expect the company to report an earnings per share (EPS) loss of 40 cents.

Additionally last week, Cassava announced plans to extend its open-label extension trials for simufilam by up to 36 months, allowing patients from previous trials to continue their treatment while awaiting Phase 3 trial results.

In Memoriam: Cassava Sciences ( SAVA ) also mourns the loss of long-time board member Sanford “Sandy” Robertson, who served on the Board of Directors since the company’s inception as a public entity in 1998.

SAVA Price Action: Cassava Sciences ( SAVA ) shares were up by 20.9% at $35.20, according to Benzinga Pro.

See Also:

Elon Musk’s New Lawsuit Against OpenAI: Accusations Of ‘Betrayal’ And ‘Deception’